New Advances in the Management of Sarcoidosis - webinar with Dr. Dan Culver

The week of February 9th was Sarcoidosis Lung Week at the American Thoracic Society (ATS). To help celebrate this week FSR will hosted a webinar with Dr. Dan Culver, which can still be viewed online: View Webinar

Over 2100 publications on Sarcoidosis & ILD in 2013 - Aim for 3000 in 2014?

2013 over 2100 publications (click here for the complete pubmed overview) on sarcoidosis and ILD were published according to this search on pubmed. We - scientific community - could aim for 3000 in 2014, but is that realistic? Read on and find out!

New issue of Sarcoidosis vasculitis and diffuse lung disease

As part of its ongoing program to highlight expertise and excellence in healthcare, is very pleased to recognize the top institutions and individual specialists in the world in sarcoidosis research and treatment. You will find WASOG well-represented.

Top Medical Specialists in Sarcoidosis

As part of its ongoing program to highlight expertise and excellence in healthcare, is very pleased to recognize the top institutions and individual specialists in the world in sarcoidosis research and treatment. You will find WASOG well-represented.

ILD Conference, Prague 2014 - preliminary programme & call for abstracts

We are pleased to invite you to the  conference and postgraduate course on "Fibrosing interstitial lung diseases of idiopathic and exogenous origin - Phenotype approach" which will be held in the beautiful city of Prague (Czech Republique), June 19-21, 2014. View our flyer. Visit the official website at    

The FSR Physicians’ Treatment Protocol

FSR (Foundation for Sarcoidosis Research) is committed to addressing the gaps that exist in sarcoidosis research. This includes the lack of information and knowledge around the current disease treatment options. Yet another challenge of “rare disease” is the inherent rarity of specialists and experts that can help guide treatment options. While physicians who specialize in sarcoidosis can be found, many times patients and doctors are challenged by a lack of information. FSR’s Scientific Advisory Board developed a mobile-friendly Physicians’ Treatment Protocol that can offer expert information to physicians to help guide their diagnosis and treatment decisions.

Pulmonary Sarcoidosis: A Guide for the Practicing Clinician

Pulmonary Sarcoidosis: A Guide for the Practicing Clinician is a valuable resource for clinicians of varied disciplines concerning the care of the sarcoidosis patient. Chapters are written by distinguished authors who have extensive experience in caring for these patients. This guide is fully comprehensive and evidence-based and will be an essential addition to the bookshelves of all whose practice involves the care and treatment of patients with sarcoidosis. More details & order online

MTX app for iPhone, iPad & Android

This app provides recommendations for the use of methotrexate in sarcoidosis and everything else you need to know about methotrexate. The app was developed on behalf of WASOG and is now available for iOS and Android. Details & Download


The 3rd combined WASOG and BAL meeting will be held in Turkey on 8-11 October 2014. On behalf of the WASOG and Turkish Thoracic Society we are pleased to invite you to the congress. The congress will be held in Kusadasi which is a resort town near Izmir and ancient Ephesus.

For details visit the official congress website at

Follow WASOG on LinkedIn, Twitter and via our e-Newsletter

In addition to this website WASOG will keep you informed using several media. Updates include WASOG news, conference updates and other relevant information we would like to share with you. We therefore invitite you to subscribe to our e-Newsletter and/or follow @wasog on Twitter. You may also join our group on LinkedIn to expand your professional network and participate in discussions.

Sarcoidosis and other ild around the world

To inform you about sarcoidosis and other ild in different countries we ask(ed) colleagues to summarize the prevalence, the research and important websites, etc. This topic has been added to the WASOG site. Read more


Highlighted Literature

Pulmonology meets rheumatology in sarcoidosis: a review on the therapeutic approach by Drent M. et al. The pathogenesis of sarcoidosis is not fully elucidated. An exaggerated granulomatous reaction after exposure to unidentified antigens in genetically susceptible individuals evokes a clinical situation which we call sarcoidosis. Between 20 and 70% of patients need systemic therapy. No firm guidelines exist on whether, when, and how treatment should be started. Treatment is dependent on the presentation and the distribution, extensiveness and severity of sarcoidosis. Treatment of Löfgren's triad-related symptoms starts with NSAIDs; in other more extensive manifestations of sarcoidosis, the initiating dosage of glucocorticosteroids is approximately 20 mg daily. In terms of evidence-based treatment for sarcoidosis, only a few randomized controlled trials have been done. Identified associations of certain polymorphisms with severity of the disease and treatment response suggest future research questions as well as finding the cause(s) of sarcoidosis, and the elucidation of relevant biomarkers and new efficient treatments. The increased awareness of long-term side-effects of glucocorticosteroids and the emergence of new drugs have changed the treatment of sarcoidosis. Read more or View Video Abstract ►

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials by Lesley Ann Saketkoo, et al. Rationale Clinical trial design in interstitial lung diseases (ILDs) has been hampered by lack of consensus on appropriate outcome measures for reliably assessing treatment response. In the setting of connective tissue diseases (CTDs), some measures of ILD disease activity
and severity may be confounded by non-pulmonary comorbidities. Identification of consensus preliminary domains and instruments to measure them was attained and is a major advance anticipated to facilitate multicentre RCTs in the field. Read full paper ►

An official American Thoracic Society/European Respiratory Society Statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias by Travis WD et al by Travis WD et al. In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, and provided standardized terminology and diagnostic criteria. In addition, the historical "gold standard" of histologic diagnosis was replaced by a multidisciplinary approach. The objective of this statement is to update the 2002 ATS/ERS classification of IIPs. The clinical course of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia is recognized to be heterogeneous. Acute exacerbation of IIPs is now well defined. A substantial percentage of patients with IIP are difficult to classify, often due to mixed patterns of lung injury. A classification based on observed disease behavior is proposed for patients who are difficult to classify or for entities with heterogeneity in clinical course. This update is a supplement to the previous 2002 IIP classification document. It outlines advances in the past decade and potential areas for future investigation. Read more ►

Ten misconceptions about antioxidants by Bast & Haenen. Oxidative damage is a common cellular event involved in numerous diseases and drug toxicities. Antioxidants prevent or delay oxidative damage, and therefore there has been extensive research into the discovery of natural and newly designed antioxidants. Initial excitement regarding the potential health benefits of antioxidants has diminished. Currently, it is even claimed that antioxidants increase mortality. The antioxidant pendulum appears to swing from healthy to toxic and from general panacea to insignificant ingredient. Owing to the polarity of views towards antioxidants, nutritional recommendation ranges from advice to increase antioxidant status in plasma to the notion that it is a useless measurement. Such views, lacking sufficient scientific support, lead to misconceptions, which in our opinion hinder the rational use of food supplements and impedes the design and development of new antioxidant drugs. As a result, good opportunities might easily be missed. Read more ►

Find all our selected literure, inluding archived pubmed selections, on our key papers page!



WASOG - World Association of Sarcoidosis and Other Granulomatous Disorders - WASOG, join wasog, wasog congresses, wasog meetings, wasog journal, wasog members, wasog history, wasog mission, wasog goals, wasog case report, wasog publications, wasog key papers